Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Fundación Pública Andaluza Progreso Y Salud maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution profile is currently limited to 1 distinct examiner and 1 distinct art unit, indicating a focused entry into the United States patent system. This concentration means that the entirety of the company's current pending legal challenges is localized within a single administrative division of the patent office.
The busiest examiner identified in the data is EBBINGHAUS, BRIANA NOEL, who is currently processing 1 busiest examiner pending office action. Since this represents the only pending action for the company, the examiner's individual approach to Biotechnology & Pharmaceuticals will dictate the immediate outcomes for the portfolio. The involvement of only 1 distinct art unit suggests that the underlying technology has not yet triggered cross-disciplinary examination.
For the practitioner, this means that the prosecution strategy does not need to account for conflicting requirements from different art units or examiners. Success depends on resolving the 1 pending office action by addressing the specific concerns of EBBINGHAUS, BRIANA NOEL. A thorough analysis of this examiner's past behavior within the 1 distinct art unit is recommended to optimize the response strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EBBINGHAUS, BRIANA NOEL | 1 | 61.6% | +63.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17293845 | POLYNUCLEOTIDE FOR SAFER AND MORE EFFECTIVE IMMUNOTHERAPIES | EBBINGHAUS, BRIANA NOEL | 15d |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17293845 | POLYNUCLEOTIDE FOR SAFER AND MORE EFFECTIVE IMMUNOTHERAPIES | EBBINGHAUS, BRIANA NOEL | 1632 | §103 | Final Rejection | 15d | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial